EVH

The past six months have been a windfall for Evolent Health’s shareholders. The company’s stock price has jumped 48.6%, hitting $3.70 per share.

Expanded Partnership Strengthens Language Access and Provides Greater Visibility Across Evolent’s Payer Network Key Takeaways Enterprise-wide telephonic interpretation expands language access for members with limited English proficiency.Centralized reporting improves oversight of language services and supports compliance efforts.AI-enabled technology and professional interpreters deliver fast, reliable service.

Looking back on healthcare technology for providers stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Evolent Health (NYSE:EVH) and its peers.

Evolent Health’s second quarter results drew a significant positive market reaction, reflecting outperformance versus Wall Street’s expectations on both revenue and profitability.

Highmark launch drove 47% revenue growth; AI platform reached meaningful scale.

Healthcare solutions company Evolent Health (NYSE:EVH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 46.9% year on year to $652.5 million.

Evolent Health (NYSE:EVH) reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May launch of its Highmark partnership and continued growth in its Performance Suite business.

Moby summary of Evolent Health, Inc.'s Q2 2026 earnings call

Evolent Health Inc (EVH) delivers robust Q2 2026 results with record revenue and EBITDA, while navigating Medicaid headwinds and setting sights on 25%+ growth in 2027.

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Evolent Health (EVH) delivered earnings and revenue surprises of +300.00% and +6.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?